<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004056</url>
  </required_header>
  <id_info>
    <org_study_id>9822</org_study_id>
    <secondary_id>POG-9822</secondary_id>
    <secondary_id>CDR0000067253</secondary_id>
    <nct_id>NCT00004056</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
  <official_title>Treatment of Newly Diagnosed Childhood AML Using a Timed-Sequential Remission Induction and Consolidation Followed by Single Dose Melphalan With Peripheral Stem Cell Rescue: A POG Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give
      higher doses of chemotherapy drugs and kill more cancer cells.

      PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy followed by
      melphalan and peripheral stem cell transplantation in treating children who have newly
      diagnosed acute myeloid leukemia that has not been treated previously.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the feasibility and toxicity of timed sequential remission induction
      and consolidation in children with newly diagnosed acute myeloid leukemia. II. Determine the
      feasibility and toxicity of a single high dose of melphalan with peripheral blood stem cell
      rescue following an intense timed sequential induction and consolidation in these children.

      OUTLINE: This is a multicenter study. Remission induction: Patients receive daunorubicin IV
      over 15 minutes on days 1-3, cytarabine IV continuously on days 1-7, oral thioguanine daily
      on days 1-7, and cytarabine intrathecally (IT) on day 1. Cytarabine IV over 3 hours is
      administered every 12 hours on days 10-12. Filgrastim (G-CSF) is administered IV or
      subcutaneously (SQ) beginning on day 13 and continuing until blood counts recover. On
      approximately day 28, patients undergo a bone marrow aspirate and biopsy to assess response.
      Patients who have attained an M1 or M2a status proceed to consolidation or, if a 5/5 or 6/6
      HLA matched sibling donor is available, proceed to allogeneic bone marrow transplantation.
      Patients with greater than 25% blasts go off study. Consolidation 1: Patients receive
      daunorubicin IV over 15 minutes on days 1 and 2, cytarabine IV over 3 hours every 12 hours on
      days 1, 2, 8, and 9, and asparaginase on days 2 and 9. G-CSF IV or SQ begins on day 10 and
      continues until blood counts recover. Consolidation 2: Patients receive cytarabine IV over 3
      hours every 12 hours on days 1, 3, and 5. G-CSF IV or SQ begins on day 6 and continues until
      blood counts recover. Peripheral blood stem cells (PBSC) are collected after the second
      course of consolidation. Consolidation 3: Treatment is repeated as in consolidation 1.
      Patients who remain in morphologic remission after consolidation 3 proceed with therapy.
      Patients receive melphalan IV over 30 minutes on day -2, then PBSC are reinfused on day 0.
      G-CSF IV or SQ begins on day 1 and continues until blood counts recover. Patients are
      followed every 6 months for 4 years and then annually thereafter.

      PROJECTED ACCRUAL: A total of 20-30 patients will be accrued for this study within 8 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">October 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility and toxicity of an intensive regimen that uses timed-sequential therapy</measure>
    <time_frame>Length of study</time_frame>
    <description>To determine the feasibility and toxicity of an intensive regimen that uses timed-sequential therapy as a strategy for both remission induction and consolidation of newly diagnosed children with AML.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility and toxicity of a single high dose of melphalan with peripheral stem cell rescue</measure>
    <time_frame>Length of study</time_frame>
    <description>To test the feasibility and toxicity of a single high dose of melphalan with peripheral stem cell rescue following an intense timed-sequential induction and consolidation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Make observations regarding PCR evidence of Minimal Residual Disease</measure>
    <time_frame>Length of study</time_frame>
    <description>To make observations regarding PCR evidence of Minimal Residual Disease in patients with relevant specific translocations who obtain a clinical remission.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Chemo + STEM cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Chemo + STEM cell</arm_group_label>
    <other_name>Granulocyte Colony-Stimulating Factor</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>GCSF</other_name>
    <other_name>NeupogenÂ®</other_name>
    <other_name>NSC #614629</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asparaginase</intervention_name>
    <arm_group_label>Chemo + STEM cell</arm_group_label>
    <other_name>E. coli</other_name>
    <other_name>Elspar</other_name>
    <other_name>NSC #109229</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <arm_group_label>Chemo + STEM cell</arm_group_label>
    <other_name>cytosine arabinoside</other_name>
    <other_name>AraC</other_name>
    <other_name>Cytosar</other_name>
    <other_name>NSC #063878</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
    <arm_group_label>Chemo + STEM cell</arm_group_label>
    <other_name>daunomycin</other_name>
    <other_name>DNR</other_name>
    <other_name>Cerubidine</other_name>
    <other_name>NSC #82151</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <arm_group_label>Chemo + STEM cell</arm_group_label>
    <other_name>L-phenylalanine mustard</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>Alkeran</other_name>
    <other_name>NSC #008806</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thioguanine</intervention_name>
    <arm_group_label>Chemo + STEM cell</arm_group_label>
    <other_name>6-thioguanine</other_name>
    <other_name>6-TG</other_name>
    <other_name>NSC #000752</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>Chemo + STEM cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven, previously untreated primary acute myeloid
        leukemia (AML) Isolated granulocytic sarcoma (myeloblastoma) allowed Patients with
        cytopenias and bone marrow blasts greater than 5% but less than 30% eligible only if there
        is karyotypic abnormality characteristic of de novo AML (t(8;21), inv16, t(9;11), etc.) OR
        unequivocal presence of megakaryoblasts No acute promyelocytic leukemia (M3) No Down
        syndrome

        PATIENT CHARACTERISTICS: Age: 21 and under Performance status: Not specified Life
        expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 3
        times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL Uric acid no
        greater than 8.0 mg/dL Cardiovascular: Cardiac function normal by echocardiogram Pulmonary:
        No uncontrolled, life threatening pneumonia Other: No uncontrolled, life threatening sepsis
        or meningitis Not pregnant Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: No prior therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig A. Hurwitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Maine Children's Cancer Program at Barbara Bush Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123-4282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital, Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Children's Cancer Program</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Oncology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tomorrows Children's Institute</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-9154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hurwitz CA, Chang M, Graham M, et al.: Timed-sequential remission induction and intensification followed by stem cell rescue for childhood AML -a POG pilot study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1553, 2002.</citation>
  </results_reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>May 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2004</study_first_posted>
  <last_update_submitted>July 24, 2014</last_update_submitted>
  <last_update_submitted_qc>July 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>childhood acute monoblastic leukemia and acute monocytic leukemia (M5)</keyword>
  <keyword>childhood acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>childhood acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>childhood acute myelomonocytic leukemia (M4)</keyword>
  <keyword>childhood acute erythroleukemia (M6)</keyword>
  <keyword>childhood acute megakaryocytic leukemia (M7)</keyword>
  <keyword>childhood acute minimally differentiated myeloid leukemia (M0)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

